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Abstract 
Women with cardiovascular disease experience a significantly greater burden of 
psychosocial distress than men. Clinical practice guidelines promote screening in cardiac 
rehabilitation (CR). 
The objectives of this thesis were to describe the burden of psychosocial distress, 
screening, forms of treatment, awareness of elevated symptoms, and whether receipt of 
treatment was related to subsequent psychosocial distress symptom severity, within 
women referred to CR. 
This study presents a secondary analysis of a multi-centre trial of women outpatients 
randomized to 1 of 3 CR models. Consenting participants were asked to complete an 
initial and follow-up survey 6 months later, and clinical data were extracted from charts. 
Findings reiterate that despite clinical recommendations, few women reported being 
screened for psychological distress, and when screened, only approximately 1/5th were 
informed of their results. When treated, most women were prescribed anti-depressants by 
their family doctor. Unfortunately therapy was not related to improvements in symptoms. 
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Introduction 
Globally, cardiovascular disease (CVD) is the leading cause of mortality. In 2008, 
an estimated 17.3 million people died as a result of CVD, which represents 30% of all 
global deaths1• Depression and anxiety are two of the most frequent co-morbidities of 
CVD. It has been estimated that approximately 30% of patients who have been 
hospitalized for a myocardial infarction (Ml) display depressive symptoms, in which 15 
to 20% suffer from major depression2'3 .The prevalence of anxiety has been less-studied 
than depression, but there is an understandable elevation of anxious symptoms in patients 
with CVD4• Lane et al. 5 found that 26% of patients who had been hospitalized for an MI, 
displayed elevated anxiety scores, and when revaluated at four and twelve months, the 
prevalence of anxious symptoms increased to 41.8% and 40.0%, respectively. Both 
depressive and anxious symptoms post-MI are associated with an increased risk of 
experiencing recurrent cardiac events6. Specifically, co-morbid depression is related to 
two-times the risk of mortality in patients with CVD7• Furthermore, co-morbid 
depression is inversely related to the adoption of secondary prevention behaviours, 
including smoking cessation and participation in cardiac rehabilitation (CR)2. 
The prevalence of major depression is greater in women with CVD compared to 
men. Specifically, the prevalence of depression in women with CVD is two-times greater 
than men 8• Moreover, it has been reported that women also tend to be at a greater risk of 
experiencing anxiety after a cardiac event9' 10• There are few reports of successful 
treatment of these co-morbid conditions among women in the literature. 
Cardiac rehabilitation (CR) is a multidisciplinary outpatient program focused on 
improving and maintaining cardiovascular health through, exercise, education, and 
counselling11 • The Canadian Association of Cardiac Rehabilitation (CACR) identifies 
exercise training as one of the core elements of CR 11 • Exercise training is a major 
component of CR that has been shown to significantly improve exercise capacity, plasma 
lipids, and overall quality of life12• Exercise-based CR has also been shown to have 
significant psychosocial benefits and CR practice guidelines promote depression and 
anxiety screening in CR3' 11 ' 13-15 . The primary objective of this prospective study is to 
describe the burden, screening, and treatment of depressive and anxious symptoms 
among women participating in CR, as well as the effectiveness of treatment. 
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Literature Review 
CVD is defined as a group of conditions that affect the function and structure of 
the heart and blood vessels1' 16• Coronary artery disease (CAD) is one of the most 
common types of CVD. CAD is characterized by problems with the circulation of blood 
to the heart muscle17• The most common cause of this circulation problem is a build-up of 
fatty deposits on the inner walls of the coronary arteries1• Blockage of the coronary 
arteries can result in a lack of oxygenated blood being delivered to the heart, which can 
cause chest pain. A myocardial infarction, also known as a heart attack, occurs when 
there is a complete blockage of a coronary artery. This results in damage or death to part 
of the heart tissue17• 
Burden of Cardiovascular Disease in Women 
Globally, CVD is the leading cause of morbidity and mortality in women, with 
8.6 million lives lost every year18' 19• In Canada, CVD is the number one killer of 
women
20
• In 2008, CVD accounted for 29.7% of all deaths in Canadian women21 . With 
advances in treatment, mortality rates in men are on the decline in the developed world, 
while mortality rates in women remain stable22. 
In addition to this burden of morbidity, women with heart disease are at particular 
risk for several reasons. First, certain risk factors of CVD are more common in women 
than men. It has been reported that women are less active than men22. Certain barriers to 
physical activity, including family responsibilities, often affect women to a greater 
extent22• In addition, having a low socioeconomic status puts women at an even greater 
risk of developing CVD than men. Although low socioeconomic status puts both men and 
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women at an increased risk of CVD, it has been reported that women experience a 61 % 
increased risk of CVD mortality, while men only experience a 29% increased risk22• 
Finally, the prevalence of psychosocial risk factors, such as depression, is higher in 
women compared to men. This discrepancy in prevalence begins at puberty and continues 
throughout adulthood, with depression being two-times greater in women8•22•23• 
Second, women experience CVD differently than men. There are sex differences 
in disease presentation between men and women, with women often experiencing 
atypical symptoms. Subsequently, women tend to be under-diagnosed22•24•25 • It has been 
found that women often present to the hospital later after the onset of symptoms, wait 
longer for treatment, and are less likely to be admitted to intensive care settings22• When 
women receive treatment, they are less likely than men to undergo aggressive treatment 
such as revascularization22'25 • 
Finally, research has shown that women may have a poorer prognosis after 
experiencing a cardiac event than men. It has been documented that women experience 
longer hospital stays, more discomfort, greater activity restriction, and disability22• In 
addition, women may have higher mortality rates compared to men. The Framingham 
study was initiated to identify factors associated with CVD by following their 
development over a long period, in a large group of participants26• Researchers found 
that initial and 1-year after infarction mortality rates were higher in women, with 44% 
mortality in women and only 27% in men25 . Moreover, women have lower utilization 
rates of secondary prevention programs, such as CR22'25 . In addition to low enrollment 
rates, women also have higher dropout rates25 • 
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Co-morbid Depression and Anxiety in Cardiovascular Disease 
Depression and anxiety fall under the broad umbrella of mood disorders, which 
are characterized by having a disturbance in disposition as their prominent feature. The 
DSM-IV-TR27 defines a major depressive episode as a period of at least two-weeks in 
which there is either depressed mood or the loss of interest or pleasure in nearly all 
activities. The individual also must experience at least four additional symptoms, 
including changes in weight or appetite, changes in sleep, decreased energy, feelings of 
worthlessness, difficulty concentrating, and suicidal ideation27• For an individual to be 
diagnosed with generalized anxiety disorder they must experience persistent and 
excessive worry in a variety of situations for a period of at least 6 months. They must also 
experience at least three additional symptoms on most days of the week, including 
constant worrying, inability to relax, difficulty concentrating, irritability, feeling tense, 
and trouble sleeping27• Note that there is a difference between clinical and non-clinical 
depression and anxiety. Clinical depression and anxiety are persistent, cause social and/or 
occupational impairment, and must be diagnosed through structured assessment by a 
trained clinician27• 
Co-morbid depression is related to twice the odds of mortality in patients with 
CVD7• A meta-analysis of 22 studies, which assessed the association between depression 
following an MI and cardiovascular prognosis found that post-MI depression was 
significantly associated with both all-cause and cardiac mortality28• Frasure-Smith et al.29 
found that in hospital depression was a significant predictor of one-year mortality post-
MI, where the rate of cardiac death for depressed women was 8.3% compared to 2.7% in 
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non-depressed women. In addition, depression after a cardiac event is related to an 
increased risk for new cardiovascular events, rehospitalization, and decreased patient 
adherence to secondary prevention strategies, including smoking cessation and 
participation in CR 2•28• Although anxiety is often one of the earliest psychological 
responses to a cardiac event, it tends to be less investigated6•10•13 . Strik et al.6 examined 
both depressive and anxious symptoms in patients following an Ml. They found that both 
depressive and anxious symptoms post-MI were associated with an increased risk of 
experiencing recurrent cardiac events. Moreover, Rothenbacher et al.30 found that CVD 
patients participating in an inpatient CR program with symptoms of anxiety had a 
statistically significant hazard ratio of2.32 for experiencing recurrent fatal and non-fatal 
cardiovascular events compared to other patients, during a 3-year follow-up period. 
Depression and anxiety are quite common in patients with CVD. Approximately 
30% of patients display depressive symptoms, with 15-20% of patients suffering from 
major depression2•3• A review by Thombs et al.31 reported that the prevalence of major 
depression in patients following an MI was 19.8%. Moreover, the prevalence of 
significant depressive symptoms based on Beck Depression Inventory-II (BDI-11) scores 
in post-MI patients was 31.1 %. Women tend to be at a greater risk of experiencing 
depression after a cardiac event. Frasure-Smith et al. 32 reported that women are about 
twice as likely to be depressed following an MI than men. They found that 24.5 % of 
women experienced in-hospital depression following an MI, while only 13.3% of men 
experienced this outcome. A study, which examined the prevalence and persistence of 
anxious symptoms in post-MI patients, found that 26% of patients displayed elevated 
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anxiety scores, and when re-evaluated at four and twelve months, the prevalence rates of 
anxious symptoms increased to 41.8% and 40.0%, respectively5. Women also tend to be 
at a greater risk for developing anxious symptoms following a 'cardiac event compared to 
men. It has been reported that women are significantly more anxious upon entry to CR 
than men9' 10• 
Since depression and anxiety are two of the most common co-morbidities of 
CVD, in-hospital screening of depressive and anxious symptoms is recommended to 
identify those patients who· may require treatment33. In addition, CR guidelines 
recommend that all patients undergo screening at program intake and receive treatment, if 
· d1114 0 fCR h . . . . reqmre ' . ne core component o t at 1s mcons1stent across programs 1s 
psychosocial distress screening34'35 . There tends to be controversy over the treatment of 
depression, as there is little capacity to do so. Many programs do not have qualified 
mental health professionals on staff34• Moreover, it has not been established that 
treatment can improve clinical outcomes36, however, there is some preliminary evidence 
that depressive and anxious symptoms can be moderately alleviated37,38 . 
As depression is related to increased morbidity and mortality in patients with 
CVD, number trials have been performed to assess whether treatment can alleviate this 
increased risk. Primary treatments for depression and anxiety include pharmacology and 
psychotherapy39-46. The majority of the major CVD and depression studies, found that 
anti-depressants, specifically selective serotonin reuptake inhibitors (SSRis), 
psychotherapy, or a combination of the two, are safe to use in cardiac patients and 
improve psychological outcomes, however it is not well established if this translates into 
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improved cardiac outcomes37•41 '44.46. There is emerging evidence that psychosocial 
treatment, including psychotherapy and a combination psychotherapy and pharmacology, 
not only reduce psychosocial distress, but may reduce the risk of recurrent MI' s and 
improve overall prognosis45•47• 
Research in the area of CVD and depression has shown that treatment of 
depression in women with CVD may be hazardous. The Montreal Heart Attack 
Readjustment Trial48 demonstrated that women randomized to a psychological nursing 
treatment displayed higher cardiac (p=0.051) and all cause mortality (p=0.064) compared 
to usual care. Furthermore, although not statistically significant, women in the Enhancing 
Recovery in Coronary Heart Disease Patients (ENRICHD) trial, favoured usual care, 
which differs from men who favoured treatment in the form of psychotherapy, or a 
combination of psychotherapy and pharmocolgy46• Results of these studies suggest that 
there may be possible differential effects of psychosocial treatment between genders46•48 . 
It is clear that further research examining treatment of psychosocial distress in women is 
needed. 
Cardiac Rehabilitation in the Management of Cardiovascular Disease and Depression 
The Canadian Association of Cardiac Rehabilitation 11 has defined CR as the 
enhancement and maintenance of cardiovascular health through individualized programs 
designed to optimize physical, psychological, social, vocational, and emotional status. 
This process includes the facilitation and delivery of secondary prevention through risk 
factor identification and modification in an effort to prevent disease progression and the 
recurrence of cardiac events. Exercise-based CR is an effective outpatient disease 
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management program 49, and there is a multitude of evidence based research that 
demonstrates the benefits of CR. Most notably, a systematic review and meta analysis of 
34 exercise-based CR randomized control trials, found that compared to usual care, 
participation in exercise-based CR was associated with a 4 7% lower risk of reinfarction, 
26% reduction in all cause mortality, and a 36% reduction in cardiac morality50• 
Additionally, participation in CR has been found to increase survival after cardiovascular 
hospitalization51 , improve exercise capacity, reduce cardiac risk factors, and have 
psychological benefits52'53 • Moreover, CR is also beneficial to the healthcare system. It 
has been reported that participation in CR reduces healthcare costs54' 55, as it is associated 
with reduced hospital readmissions54,56• 
Physical activity is the central component of CR 11 ' 14• Numerous studies have 
demonstrated the beneficial effects that CR and specifically exercise have on an 
individual's cardiovascular and psychological health3'9'52'53'57. Lavie et al. 57 reported that 
individuals who participated in CR had significant reductions in body mass index, 
percent body fat, resting heart rate, and resting systolic blood pressure. Moreover, CR 
participants displayed increased high density lipoprotein (HDL ), and peak maximum 
oxygen consumption. The same improvements were seen when specifically looking at 
women. In one study women had a 33% improvement in exercise capacity and a 7% 
reduction in percent body fat52• In addition, exercise has been shown to reduce the 
psychosocial distress among patients participating in CR58. In one study individuals 
showed marked improvements on both depression and anxiety scores on the Symptom 
Questionnaire (SQ), with reductions of 58.5% and 46.0%, respectively after attending 
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CR. Participants also experienced a 15.8% increase in overall quality of life, which was 
assessed by the Short Form Health Survey (SF-36)57. The same trend is seen when 
looking exclusively at women. Lavie et al.3 reported that after attending CR, depressed 
women showed improvements on both depression and anxiety scores on the Symptom 
Questionnaire (SQ), with reduction of 55% and 54%, respectively. Women also displayed 
a 30% increase in overall quality oflife, measured by the Sort Form Health Survey (SF-
36). Following CR, the prevalence of depression in the study sample nearly dropped in 
half, from 23 % to 12%. 
As there is clear relationship between CVD and mood disorders59, CACR11 and 
American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)15 
recommend that all CR patients undergo screening for depression and anxiety. Moreover, 
The Canadian Network for Mood and Anxiety Treatments (CANMA T) state that co-
morbidities, such as mood disorders must be properly diagnosed and treated to ensure 
optimal patient outcomes59• After such screening, any individuals who screen positive for 
depression or anxiety should be referred to a qualified professional, such as a 
psychologist or psychiatrist, for formal assessment and treatment, as necessary11 . 
Furthermore, the guidelines recommend that any patients who report ongoing stress, but 
do not have active depression or anxiety should be offered a stress management program. 
Stress management programs or group sessions that focus on psychosocial issues may be 
beneficial, as psychosocial problems are common in the cardiac population and can have 
unfavorable effects11 • 
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Despite these recommendations, rates of psychosocial distress screening in CR 
programs are inconsistent. In a recent study evaluating the core components of CR 
programs in Ontario, 68.4% of programs screened patients for depressive symptoms34. In 
an earlier American study, only 36% of programs screened for depression35• Low rates of 
psychosocial distress screening in CR programs may be due to capacity issues34• 
Screening for and treatment of psychosocial issues are an important component of CR as 
patients with psychosocial distress may be more likely to drop out compared to patients 
without depression. Grace et al. 60 found a significant inverse relationship between 
depressive symptomatology and number CR exercise session attended. Furthermore, 
minimal psychosocial interventions were offered. 
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Objectives 
The objectives of this thesis were to: (1) describe rates of psychosocial distress 
screening, as well as outcome of such screening; and (2) describe women's awareness of 
elevated depressive and/or anxious symptoms. In addition, (3) in women with elevated 
symptoms, the aim was to: (a) describe the proportion treated, (b) the types of treatments 
received, and ( c) the type of provider from whom they received treatment. In the case of 
pharmacological treatment, the aim was to: (3d) describe the class of medication, (3e) 
patient adherence, and (3f) ifthe medication had been changed or titrated since pre-
testing. Finally, the last objective was to: (4) to describe whether receipt of treatment was 
related to depressive/anxious symptom severity at post-test. 
It is hoped the current study will inform clinical and scientific audiences on the 
importance of screening in the CR setting, how CR programs are performing in this 
regard, and the effects for patients. 
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Manuscript Preface 
This thesis is prepared in manuscript style. Participants were recruits from a larger 
study involving six CR programs across Ontario, Canada (Appendix A). Participants 
were described based on chart-reported clinical characteristics (Appendix Band C) and 
self-reported sociodemographic characteristics (Appendix D). All objectives were 
assessed through self-report surveys, which consisted of investigator-generated and 
psychometrically-validated scales (Appendix E, F, G, H, I, Kand L). The study was 
approved by the Research Ethics Boards of the participating hospitals, as well as York 
University's Office of Research Ethics (certificate#: 2009 - 323). The results of this 
study are presented in the manuscript which follows. 
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Abstract 
Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity 
and mortality among women. Women with CVD experience a greater burden of 
psychosocial distress than men, and practice guidelines promote screening in cardiac 
patients. 
Objectives: To describe the burden of psychosocial distress, screening and forms of 
treatment among women cardiac patients. Also to describe awareness of elevated 
symptoms and whether receipt of treatment was related to post-test psychosocial distress 
symptom severity. 
Methods: Within a multi-centre trial of women randomized to 1 of 3 cardiac 
rehabilitation models, consenting participants were asked to complete surveys upon 
consent and 6 months later. Clinical data were extracted from charts. This study presents 
a secondary analysis of the surveys, including the Hospital Anxiety and Depression 
Scale. 
Results: Of the 111 (79.9%) participants retained, 44 (42.8%) self-reported that they 
recalled being screened, and of these, 8 (18.6%) reported discussing the results with a 
healthcare professional. Sixty-eight ( 48.9%) participants had elevated symptoms of 
psychosocial distress at pre-test, of which 18 (26.5%) appeared to be unaware. Twenty-
one ( 42.9%) participants were receiving treatment. Regression analyses showed that 
treatment of psychosocial distress was not significantly associated with post-test 
depressive or anxious symptom severity. 
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Conclusions: Findings reiterate the great burden of psychosocial distress among women 
with CVD. Despite clinical recommendations, results suggest few women report being 
screened, and when screened, only approximately 1 in 5 women were informed of their 
results. Less than half of patients with elevated symptoms were treated, and the treatment 
approaches did not appear to reduce symptoms. 
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Introduction 
Globally, cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality in women and men, representing 30% of all deaths worldwide1• Depression and 
anxiety are two of the most frequent co-morbidities of CVD, increasing the overall 
impact of the disease. Approximately 30% of patients who have been hospitalized for a 
myocardial infarction experience depressive symptoms, of which 15 to 20% suffer from 
major depression2• The prevalence of anxiety has been less-studied, but there is an 
understandable elevation of anxious symptoms following an acute CVD event3• 
Moreover, both depressive and anxious symptoms post-myocardial infarction are 
associated with an increased risk of experiencing recurrent cardiac events4• Co-morbid 
depression is related to twice the risk of mortality in patients with CVD5 and is inversely 
related to the adoption of secondary prevention behaviours, including smoking cessation 
and participation in cardiac rehabilitation (CR)2• Accordingly, cardiovascular clinical 
practice guidelines recommend routine screening for depression following a 
cardiovascular event6'7• 
The prevalence of major depression in women with CVD is twice that of men. 
Moreover, women also tend to experience greater anxiety after a cardiac event8• 
Evidence-based therapies for depression and anxiety are well-established9'10, and have 
been tested in the CVD population 11- 14• There is some emerging evidence that treatment, 
including psychotherapy, pharmacology, and a combination of the two, not only reduce 
psychosocial distress11- 15, but also can reduce the risk ofrecurrent myocardial infarctions 
and improve overall prognosis11 '16• However, there are some reports of unsuccessful 
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treatment of these co-morbid conditions among women, and in fact that psychosocial 
treatment may be associated with adverse outcomes. For instance, the results of The 
Montreal Heart Attack Readjustment Trial 17 demonstrated that women in the treatment 
arm displayed significantly higher cardiac and all-cause mortality compared to usual 
care. Moreover, minimal improvements in depressive and anxious symptom severity 
were reported. Furthermore, although not significant, results showed that outcomes for 
women in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) trial 
appeared better under usual care, compared to men who favored treatment 12. Results of 
these studies suggest that a better understanding is needed of effective psychological 
therapies for women with CVD12•17• 
Psychosocial distress screening is recommended in clinical practice guidelines for 
cardiac patients18•19• After such screening, it is recommended that any individuals who 
indicate a heightened level of symptoms of depression or anxiety be referred to a 
qualified professional, such as a psychologist, social worker or psychiatrist, for formal 
assessment and treatment, as necessary18- 20. Accordingly, the objectives of this study 
were to: (1) describe rates of psychosocial distress screening, as well as outcome of such 
screening; and (2) describe women's awareness of elevated depressive and/or anxious 
symptoms. In addition, (3) in women with elevated symptoms of psychosocial distress, 
the aims were to: (a) describe the proportion treated, (b) the types of treatments received, 
and (c) the type of provider from whom they received treatment. In the case of 
pharmacological treatment, the aims were to: (3d) describe the class of medication, (3e) 
patient adherence, and (3f) if the medication had been changed or titrated between pre 
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and post-testing; and (4) describe whether receipt of treatment was related to 
depressive/anxious symptom severity at post-test. 
Methods 
Design and Procedure 
This study presents a secondary analysis of an ongoing single-blind pragmatic 
randomized controlled trial of female CVD outpatients randomized to one of three types 
of CR, to understand the effects of program model on adherence21 . The design herein is a 
prospective cohort. 
In the original study, participants were recruited from six inpatient and outpatient 
cardiac units in the Greater Toronto Area of Ontario, Canada. Consenting and eligible 
patients were then randomized to one of three CR program models: (1) mixed-sex 
traditional hospital-based CR, (2) women-only hospital-based CR, and (3) monitored 
home-based CR (Appendix A). CR patients attending the women-only model who were 
not participating in the larger trial were also approached to participate in an observational 
sub-study, where the same assessments were administered. CR enrollment and 
participation was observed in all patients. 
Clinical information was extracted from inpatient and/ or outpatient medical charts 
(Appendix B and C). Prior to CR initiation, participants were asked to complete a self-
report survey, which included a number of standardized and validated scales assessing 
socio-demographic characteristics (Appendix D), psychosocial distress (Appendix E, F, 
and G), medication adherence (Appendix H), medications (Appendix I), and exercise 
behaviour (Appendix J). 
20 
Post-test assessments occurred six months later by mail. The self-report survey 
assessed psychosocial distress (Appendix G, Kand L), medication adherence (Appendix 
H), medication use (Appendix I), and exercise behaviour (Appendix J). Moreover, an 
audit of patient CR charts was undertaken to ascertain CR enrollment and completion 
(Appendix M). Response rate was optimized through repeated and personalized 
contacts22. This included a replacement survey mailing and telephone calls, if required. 
Participants 
Participants in this study were consenting women inpatients or outpatients with 
documented coronary artery disease (CAD), and/or acute coronary syndrome (ACS), 
and/or undergoing revascularization (percutaneous coronary intervention [PCI] or 
coronary artery bypass grafting [CABG]), and/or valve surgery. These chosen cardiac 
indications were based on CR referral recommendations18-20• 
Inclusion criteria were: patient resided in Toronto or Hamilton, within 45 minutes 
of CR site; proficiency in the English language, and eligibility for home-based CR. 
Exclusion criteria were: (1) musculoskeletal, neuromuscular, visual, cognitive or non-
dysphoric serious psychiatric condition (e.g., schizophrenia), or any serious or terminal 
illness not otherwise specified which would preclude CR eligibility based on CR 
guidelines18, (2) physician deemed patient not suitable for CR at time of intake exercise 
stress test, (3) patient planned to leave the region prior to the anticipated end of 
participation, (4) patient discharged to a long-term care facility, and (5) participation in 
another clinical trial with behavioural interventions. 
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Measures 
Sociodemographic characteristics were assessed in the initial patient survey 
through forced-choice response options, including: age, ethnic background, marital 
status, education, income, work status and dependents (Appendix D). Clinical data 
extracted from medical charts included cardiac diagnoses, risk factors, and co-morbid 
conditions (Appendix B). Exercise behaviour was also measured in the final survey, 
considering its relation to mood23'24 using the Godin Leisure-time Exercise 
Questionnaire25 . This is a brief and reliable instrument that was used to assess usual 
leisure-time physical activity behaviour during a one-week period (Appendix J). Lastly, 
CR participation was verified via an audit of participants' CR charts (Appendix M). 
Assessment of Depressive and Anxious Symptoms 
Psychometrically-validated scales were administered in both the pre and post-test 
self-report surveys to assess psychosocial distress. First, the Beck Depression Inventory-
11 (BDI-11)26 was administered to assess depressive symptoms in the pre-test survey 
(Appendix F). It is a reliable and well-validated 21-item scale that uses a 4-choice 
response format. It has been widely used in the general population and in populations 
with long-term illness, including cardiac disease. Higher scores reflect greater depressive 
symptomatology, with scores ~14 reflecting "elevated" (i.e., mild to severe) 
symptomatology. 
Second, the Patient Health Questionnaire-2 (PHQ-2)27 was administered in both 
the initial and final surveys to assess the frequency of the two cardinal features of 
depression, namely depressed mood and anhedonia (Appendix G). The PHQ-2 total score 
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ranges from 0 to 6, with score of 2:3 indicating elevated symptoms27• Finally, The 
Hospital Anxiety Depression Scale (HADS)28 was administered in the final survey, to 
additionally assess anxiety (Appendix L). The HADS is a 14-item questionnaire with 
seven items assessing anxiety and seven items assessing depressive symptoms. Each item 
is scored from 0 to 3, with each subscale scored out of 21. Scores 2:9 represented elevated 
symptoms of anxiety or depression28,29• 
Investigator-generated items assessing problems with, awareness of, and 
treatment for depression and anxiety were incorporated in both surveys (Appendix E and 
K). In the initial survey, participants were asked if they had current problems with 
depression and/or anxiety (yes/no). Participants who reported no problems, but scored 
above scale thresholds as per above, were considered "unaware". In both initial and final 
surveys, participants were also asked if they were receiving treatment (yes/no), the type 
of provider from whom they were receiving treatment, and finally the type of treatment 
they were receiving (i.e., pharmacotherapy, psychotherapy, or both). In the final survey, 
participants were asked whether they had been screened for depression and/or anxiety 
since they were referred to CR (yes/no), and the outcome of such screening. 
Use of psychoactive medication was ascertained by reviewing self-reported 
medication lists (Appendix I). Participants were asked in both initial and final surveys to 
record all medications they were currently taking, and the dose per day. Psychoactive 
drugs were coded according to their drug class30. Whether the psychoactive medication(s) 
listed were different on the pre and post-test survey was also assessed, and where the 
same medication was reported at both assessment points, whether the dosage had been 
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changed. Finally, adherence to medication was assessed via Morisky's Medication 
Adherence Scale (MMAS-4)31 , which was administered in both pre and post-test surveys 
(Appendix H). It is a brief and reliable instrument to assess medication adherence. The 
MMAS-4 total score ranges from 0-4, with any score less than 4 indicating non-
adherence. 
Analysis 
All statistical analyses were performed using SPSS version 2032• Comparisons of 
sociodemographic, clinical and psychosocial characteristics between participants retained 
and those lost-to-follow-up, as well as group differences (i.e., self-reported and/or 
elevated scores vs. no self-reported and/or elevated scores) were performed. Scores were 
compared using 2- tailed independent sample t-tests or 2-tailed chi-squared tests, as 
appropriate, with a significance cut-off value of p<0.05. The relationship between pre and 
post-test psychological distress was also explored. 
To test the first objective, a descriptive analysis of the investigator-generated item 
in the final survey, which assessed self-reported screening of depression and anxiety and 
the outcome of such screening, was performed (Appendix K). To test the second 
objective, a descriptive analysis of the investigator-generated item in the initial survey 
which asked respondents if they were currently having problems with depression and/or 
anxiety (yes/no) was performed (Appendix E). Responses were cross-referenced to 
participant symptom scores on the scales (Appendix F and G). The number of 
participants who scored above thresholds, yet did not report depression and/or anxiety, 
was described. 
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To test the third objective, participants who self-reported currently experiencing 
psychosocial distress and/or scored above the thresholds indicating elevated distress on 
the BDI-11 or PHQ-2 were first selected (Appendix N). Due to a change in survey scales 
after the study had begun, a small number of participants received the HADS scale 
instead of the BDI-11 in their pre-test survey. In this case, those that scored above 
thresholds on the HADS-D were also selected (Appendix L). A descriptive analysis of 
treatment pre and post-test was performed (Appendix E and K). Among those receiving 
treatment, description of treatment and provider type was performed. To test objectives 
d-f, participants who were prescribed pharmacological therapy were selected. Next, a 
descriptive analysis of the drug classification, medication adherence, and the frequency 
of medication and/or dosage change from pre to post-test assessment was performed 
(Appendix Hand I). 
To test the final objective, a multiple linear regression was undertaken to examine 
whether receipt of any treatment post-test (yes/no) was associated with depressive and 
anxious symptom severity at post-test (Appendix L), in those with elevated symptoms of 
psychosocial distress at pre-testing. The model adjusted for sociodemographic and 
clinical variables shown to be associated with post-test depressive and anxious symptom 
severity in bivariate analyses. 
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Results 
Respondent characteristics 
Of the 139 participants included in this analysis, 111 (79.9%) participants were 
retained at the 6-month follow-up. Table 1 displays the pre-test sociodemographic, 
clinical and psychosocial characteristics of the respondents and non-respondents. As 
shown, there were no significant differences in sociodemographic characteristics between 
groups. However, retained participants were more likely to have undergone a PCI 
compared to those lost to follow-up. No other clinical differences were found between 
retained participants and those lost to follow-up. Finally, there were no significant 
differences in depressive symptoms by retention status. 
As shown in Table 1, 49 (44.l %) retained participants experienced elevated 
symptoms of psychosocial distress at baseline. As expected, there were significant 
differences in psychometrically-validated depression scales by categorization of 
evaluated symptoms of psychosocial distress versus no distress, suggesting the 
categorization was valid. Moreover, those with elevated distress symptoms were 
significantly more likely to have a self-reported history of depression or anxiety, as well 
as self-reported history of treatment for depression or anxiety than those without distress. 
Participants with elevated symptoms were also significantly younger, had a higher body 
mass index, and were more likely to have dyslipidemia than participants without elevated 
symptoms. 
At post-test, 38 (34.5%) participants were considered to be experiencing elevated 
symptoms of psychosocial distress (no significant difference between the number of 
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women with elevated symptoms at pre and post-test; McNemar test= p>0.05; OR=4.92). 
A significant difference between pre and post-test PHQ-2 symptom scores was found for 
women with elevated symptoms at pre-test (mean difference= -0.76; paired t=3.27, p 
<0.01). Table 2 displays post-test psychosocial indicators among women with elevated 
symptoms of psychosocial distress and those without at pre-test. At follow-up, those with 
elevated symptoms at pre-test still had significantly higher symptom scores on 
psychometrically-validated scales than participants without elevated symptoms, but their 
mean scores fell below the established cut-offs. No differences in exercise behaviour, 
medication adherence or CR use were observed. 
Screening and Awareness 
Thirty-seven (34.9%) participants self-reported that they recalled being asked 
about their mood and/or anxiety by any healthcare provider at post-test. Forty-four 
(42.8%) participants reported they recalled being formally screened for psychosocial 
distress, of which 32 (31.1 % ) reported completing a paper-and-pencil screen, 4 (3 .9%) a 
structured interview, and 8 (7 .8%) reported completing both. The number of participants 
who reported being asked about their mood and undergoing formal screening did not 
significantly differ in those who ultimately enrolled in CR following referral versus those 
who did not (p=0.54 and p=0.59, respectively). 
Of those who reported being formally screened, 8 (18.6%) had their results 
discussed with them. The outcomes of formal screening were (participants were asked to 
check all that apply): appropriately nothing (n=l 7, 45.9%), pharmacology prescription 
(n=5; 13.5%), referral to a mental health professional (n=5; 13.5%), follow-up by a 
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healthcare provider (n=5; 13.5%), inappropriately nothing (n=4; 10.8%), referral for 
other mental health treatment (n=l; 2.7%), other (n=5; 13.5%), and unknown by patient 
(n=l; 2.7%). 
Sixty-eight ( 48.9%) women were considered to be experiencing elevated 
psychosocial distress at the initial assessment (of which 49 participants were retained at 
follow-up). Of these, 18 (26.5%) reported they were not anxious or depressed, and thus 
could be considered unaware that they may have a psychological disorder. 
Treatment of Distressed Women 
Of the 49 distressed women retained at post-test, 21 (42.9%) were receiving some 
form of treatment at pre-test. Of these, 18 (85.7%) were still receiving treatment at post-
test, and 3 (14.3%) were not. Of those 49 distressed women at pre-test, 23 (47.9%) were 
receiving some form of treatment at post-test (i.e., 18 patients+ 5 new). The number of 
participants receiving treatment did not significantly differ between pre and post-test 
assessment (McNemar test=p>0.05; OR=27.60). Table 3 displays the types of treatment, 
as well as who was providing it, at both assessment points. The number of distressed 
women receiving treatment, and type of treatment did not differ by CR enrollment 
(p>0.05 in all cases). 
Of those receiving treatment, 17 (80.9%) were taking psychoactive medications at 
pre-test and 21 (91.3%) were taking them at post-test. Their overall mean medication 
adherence score was 3.81±0.40 at pre-test and 3.21±1.01 at post-test, with 3 (18.8%) and 
9 (42.9%) considered "non-adherent", respectively. Table 3 also displays the class of 
psychoactive medication taken at both time points. The same medication was reported at 
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both assessment points for 10 (83.4%) participants, for which 2 (16.7%) participants 
reported a change in dosage over time (one increased and one decreased). Two (16.7%) 
participants reported a change in psychoactive medication from pre to post-test: one from 
selective serotonin reuptake inhibitor to a serotonin norepinephrine reuptake inhibitor, 
and one switched medications within the atypical class. 
Participants who were receiving any form of treatment at pre-test had 
significantly higher depressive (6.95±5.19 vs. 3.83±3.31) and anxious (10.38±4.61 vs. 
5.89±3.68) symptom scores at post-test than those who were not receiving treatment 
(p<0.001 in both cases). Similarly, participants who were receiving any form of treatment 
at post-test had significantly higher depressive (7.13±4.98 vs. 3.40±3.08) and anxious 
(10.52±4.35 vs. 5.40±3.43) symptom scores at post-test than those who were not 
receiving treatment (p<0.01 and p<0.001, respectively). Table 4 displays analysis of 
correlates of depressive and anxious symptoms at post-test. Unadjusted analyses showed 
that greater pre-test psychosocial distress symptom scores were significantly associated 
with greater depressive and anxious symptom scores at post-test. Moreover, greater post-
test exercise behaviour was found to be significantly related to lower post-test depressive 
symptom severity. 
Two multiple linear regressions were performed to ascertain whether receipt of 
any treatment (independent variable) was related to psychosocial distress scores at post-
test (i.e., HADS-D and HADS-A; dependent variables). The model was adjusted for pre-
test symptom scores and post-test exercise behaviour (i.e., significant differences 
identified in Table 5), as well as age and cardiac indication (i.e., primary significant 
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differences identified in Table 1). PHQ-2 scores were not included due to their 
correlation with BDI-II scores. The results are shown in Table 5. The models overall 
were significant (F=S.68, p<0.01; F=S.20, p=<0.01, respectively), and were amply 
powered (0.94 and 0.92, respectively). The effect of treatment on depressive or anxious 
symptom severity at post-test did not sustain adjustment, suggesting that pharmacologic 
or counseling treatments did not seem to lower symptom scores. As shown, psychosocial 
distress symptom scores at post-test were significantly related to psychosocial distress 
symptom scores at pre-test, but no other variables in the model were found to be 
significantly related. 
Discussion 
These findings reiterate the great burden of psychosocial distress among women 
with CVD33, with approximately half of women displaying elevated symptoms. Of these, 
25% were unaware or did not consider themselves to be experiencing elevated symptoms. 
Despite clinical recommendations, less than half of women cardiac patients recall being 
formally screened for depression and anxiety. Even when screened, only one in five 
recall being informed of the results. This clearly represents a gap in patient-provider 
communication. Finally, less than half of women with elevated symptoms were receiving 
treatment, but regardless, receiving treatment had no significant impact on their 
symptoms. While a structured clinical interview is needed to confirm a psychological 
disorder and whether treatment is warranted, these findings certainly corroborate 
previous reports of insufficient and even inappropriate (i.e., TCAs) treatment ofthis 
important co-morbidity. 
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Despite recommendations, depression is not routinely identified in cardiac 
patients34, a finding which was reiterated in the current study. Shanmugasegaram et al. 35 
found that only 28. 7% of coronary artery disease patients reported being screened 
following a cardiac hospitalization, and 32.5% of patients enrolled in CR reported being 
screened. While the rates in our study were somewhat higher, given that less than half of 
women recall being screened, perhaps it is not surprising that so many women with 
elevated symptoms of distress were unaware. 
Given CR-specific screening recommendations18, it was surprising that patients 
who enrolled in CR following referral did not report greater rates of screening than 
patients who did not enroll. Given women's great burden of both psychosocial distress as 
well as heart disease, the CR context presents an important opportunity to screen and 
address these co-morbidities, to improve women's psychological and potentially physical 
well-being. It is hoped results from this study will raise awareness of the importance of 
screening in the CR setting, and how CR programs are under-performing in their patient 
communication regarding screening. It is postulated that CR staff who undertake intake 
assessments including depressive symptoms may need training to improve their patient 
communication skills regarding what can be a sensitive topic. It is also suggested that 
there is insufficient capacity to ensure effective treatment is available for all patients who 
screen positive, given the chronic under-funding of CR services, which may serve as a 
deterrent to screening. 
A number of studies have examined the effect of in-hospital depression screening 
on patient outcomes36-38• Results suggest that when screening is combined with 
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"collaborative care", patients can achieve significant reductions in depressive 
36-38 M d. h 1 d . "fi . . symptoms . oreover, some stu 1es ave a so reporte s1gm 1cant improvements m 
mental health-related quality of life (HRQoL )36'37, adherence to medical 
recommendations36, physical function37 and reductions in the number and intensity of 
cardiac symptoms36 with this approach. Our results suggest that while few women 
cardiac patients recall being screened, even fewer recall being informed of the results, 
and for this reason, it is unknown if these benefits could be achieved. Given that less than 
half of the women in the study who were distressed received any form of treatment, it is 
unlikely that the above benefits could be achieved. 
Our findings are not consistent with many of the major CVD and psychosocial 
distress trials, which showed that psychoactive drugs, psychotherapy, or a combination of 
the two, improve psychological outcomes11- 14• Our data are pragmatic and observational, 
and suggest that distressed women patients are: (a) not getting sufficient therapy (b) may 
need to change or introduce additional therapeutic modalities to achieve symptom control 
and remission, or ( c) have chronic treatment-resistant depression. In the case of 
pharmacological treatment, which was the primary form of treatment in this sample, it is 
known that individuals being treated with psychoactive drugs are not put on an full 
therapeutic dose right away, to reduce the chance of side eff ects9. Patients should be 
followed-up with by their physician to observe how they are tolerating the medication, 
whether they are experiencing side effects, and to up-titrate the dose if needed (to balance 
efficacy and safety)9'39• Our results suggest patients may not be receiving adequate 
follow-up, as only 113 of those treated pharmacologically reported any change in 
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medication (i.e. type or dose change; although we acknowledge that we do not have data 
on the frequency of follow-up visits to the treating healthcare professional). It has been 
reported that only 20-30% of patients undergoing depression treatment receive adequate 
care and follow-up in the primary care setting6• Given most patients were receiving 
therapy from primary care, and the CR setting was also shown to be ineffective, perhaps 
it is time to increase the capacity of cardiac psychologists and psychiatrists to address this 
burden. 
Caution is warranted when interpreting these findings. First, the protocol did not 
include a structured clinical interview to formally diagnose depression or anxiety, so the 
number of participants with a major depressive disorder or anxiety disorder is unknown, 
as is the appropriateness of the rates of treatment. Indeed, self-report of depressive and 
anxiety symptoms is subject to under-reporting bias. Second, rates of distress screening 
and identification may be under-reported due to possible recall bias. Screening was only 
ascertained through self-report, and they may have forgotten screening that had occurred 
months prior. Indeed, the CR programs where patients were referred routinely administer 
a paper-and-pencil depression survey, however we did not verify this in CR charts. Third, 
due to the nature of the study design, causality in the relationship between the variables 
of interest and symptom control cannot be inferred. Fourth, the MMAS assesses 
adherence to medications broadly, and is not specific to psychoactive medications. 
Therefore, the degree of patient adherence to prescribed psychoactive medications cannot 
be known. Finally, results are limited by selection and retention bias. With regard to the 
former, it is not known how participants who consented to participate in this randomized 
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trial on CR differed from those who did not, however previous research has suggested 
that there are some important differences which may impact the generalizability of these 
findings40. While the only observed difference between those retained and lost to follow-
up was in the rate of PC Is, there may be unmeasured factors which introduce a bias in our 
retained sample. 
In conclusion, our findings reiterate the great burden of psychosocial distress in 
women cardiac outpatients. Despite guideline recommendations, screening rates are 
suboptimal, and communication of results to patients is minimal. Where treated, most 
women were often prescribed psychoactive medication from their family physicians, 
however substantive symptom reduction compared to those not receiving treatment was 
not achieved. 
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Table 1. Participant Characteristics at Pre-Test (N=139) 
Lost-to 
Characteristics Retained Particil!ants follow-ul! Total 
Self-reported No self-reported Total n=28 N=l39 
distress and/or distress and/or N= 111 
elevated scores elevated scores 
n=49 ~44.1%) n=62 (55.9%~ 
Sociodemographic 
Age, years (mean± SD) 62.95 ± 8.40 68.96 ± I 0.90 66.38 ± 10.30** 61.73 ± 10.10 65.54 ± 10.38 
Marital Status, n (% married) 23 (46.9) 34 (54.8) 57 (51.4) 13 (46.4) 70 (50.4) 
Work Status, n (% retired) 23 (46.9) 39 (62.9) 62 (55.9) 14 (50.0) 76 (54.7) 
Highest Education, n (%post-secondary) 13 (26.5) 24 (38.7) 37 (33.3) 9 (32.1) 46 (33.1) 
Ethnicity, n (%white) 37 (75.5) 45 (72.6) 82 (73.9) 17 (60.7) 99 (71.2) 
Annual Family Income, n (% $50,000CDN 25 (51.0) 40 (64.5) 65 (58.6) 16 (57.1) 81 (58.3) 
or greater) 
Children, n (% yes) 39 (83.0) 49 (80.3) 88 (81.5) 23 (82.1) 111 (81.6) 
Clinical 
Cardiac Indication 
PC! (%yes) 26 (57.8) 29 (50.9) 55 (53.9) 5 (21.7) 60 (48.o)tt 
Angina/ A CS/CAD (%yes) 19 (43.2) 18 (32.1) 37 (37.0) 10 (43.5) 47 (38.2) 
MI (%yes) 15 (33.3) 17 (30.4) 32 (31.7) 6 (26."l) 38 (30.6) 
CABG (%yes) 8 (17.8) 20 (35.1) 28 (27.5) 5 (21.7) 33 (26.4) 
Valve (%yes) 7 (15.6) 14 (25.0) 21 (20.8) 6 (26.1) 27 (21.8) 
BMI (mean± SD) 31.68 ± 7.82 27.86 ± 5.23 30.01 ± 7.07 .. 31.04 ± 9.28 30.24 ± 7.47 
Diabetes, n (% yes) 13 (36.1) 8 (19.5) 21 (27.3) 7 (41.2) 28 (29.8) 
Hypertension, n (% yes) 27 (73.0) 40 (81.6) 67 (77.9) 15 (78.9) 82(78.1) 
Dyslipidemia, n (%) 34 (97.1) 36 (.80.0) 70 (87.5)* 18 (90.0) 88 (88.0) 
Exercise Behavior (mean± SD) 21.97 ± 20.35 19.51±14.13 20.62 ± 17.19 17.77 ± 23.48 20.04 ± 18.60 
Psychosocial 
Self-Reported History of Depression or 22 (45.8) 13 (22.8) 35 (33.3)* 13 (52.0) 48 (36.9) 
Self-reported History of Pharmacological 11 (22.9) 7 (12.3) 18 (17.1)** 4 (16.0) 22 (16.9) 
Self-reported History of Psychotherapy for 14 (29.2) 12 (20.7) 26 (24.5)** 10 (40.0) 36 (27.5) 
BDI-II (mean± SD) 17.73 ± 12.07 5.42 ± 3.73 10.57 ± 10.26*** 10.94 ± 7.75 10.65 ± 9.75 
PHQ-2 (mean± SD) 2.11 ± 2.00 0.36 ± 0.62 1.17 ± 1.67*** 1.17 ± 1.37 1.17 ± 1.62 
PCI, Percutaneous Coronary Intervention; ACS, Acute Coronary Syndrome; CAD, Coronary Artery Disease; CON, Canadian dollars; Ml, Myocardial Infarction; CABG, Coronary Artery 
Bypass Graft; BMI, Body mass index; BDI, Beck Depression Inventory; PHQ, Patient Health Questionaire 
~ ·oenotes difference between participants with elevated vs. no elevated symptoms (p < .05; .. P < .01; ... P < .001). 
o toenotes difference between participants who were retained vs. not retained at 6 month follow-up (1p < .05; t p < .01; tttp < .001). 
Table 2. Post-Test Psychosocial and Other Indicators among Women by Psychosocial Distress Status at Pre-Test 
(N=lll) 
Variable 
Psychosocial Symptoms t 
Depressive Symptoms (P HQ-2) 
Depressive Symptoms (HADS-D) 
Anxious Symptoms (HADS-A) 
Psychosocial Distress Screening (% yes) 
Exercise Behaviour (Godin) t 
Medication Adherence (MMAS) t 
Enrolled in CR (% yes) 
Completed CR (% yes) 
Self-reported distress 
and/or elevated scores 
n=49 (44.1 %) 
1.42 ± 1.88 
5.19 ± 4.48 
7.85 ± 6.65 
21 (44.7) 
26.94 ± 17.92 
3.49 ± 0.79 
43 (87.8) 
30 (69.8) 
No self-reported distress 
and/or elevated scores 
n=62 (55.9%) 
0.37 ± 0.91 
2.42 ± 2.18 
3.65 ± 2.85 
16 (27.1) 
29.32 ± 17.94 
3.69 ± 0.67 
59 (95.2) 
40 (85.1) 
Total 
o.83 ± i.so** 
3.63 ± 3.63*** 
5.48 ± 4.27*** 
37 (34.9) 
28.25 ± 17.89 
3.63 ± 0.73 
102 (91.9) 
70 (77.8) 
PHQ, Patient Health Questionnaire; HAD-A and HAD-D, Hospital Anxiety and Depression Scale, MMAS, Morisky's 
Medication Adherence Scale 
*p < 0.05; **p <O .01; ***p < 0.001 fort-test or chi-square comparing indicators by psychosocial distress status, as appropriate. 
tmean and standard deviation. 
Table 3. Treatment of Patients who were Considered Distressed at Pre-Test, by Assessment Point 
Pre-Test Post-Test 
(n=21; 42.9% treated) (n=23; 47.9% treated) 
Treatment Type 
Medication 10 (46.7) 13 (56.5) 
Combination 7 (33.3) 8 (34.8) 
Counseling 4 (19.0) 2 (8.7) 
Type of Provider* 
Family Doctor 13 (68.4) 18 (90.0) 
Psychiatrist or Psychologist 7 (36.8) 5 (25.0) 
Other 2 (10.5) 4 (20.0) 
Nurse 1 (5.3) 2 (10.5) 
Cardiologist 1 (5.3) 2 (10.0) 
Class of Psychoactive Medication *t 
SSRI 5 (33.3) 4 (21.1) 
Atypical antidepressant§ 7 (46.7) 6 (31.6) 
Benzodiazepines 5 (33.3) 10 (52.6) 
SNRI 3 (20.0) 3 (15.8) 
TCA 2 (13.3) 2 (10.5) 
Note that some women reported receiving treatment from more than one type of provider and taking more 
than one psychoactive medication. 
SSRis, Selective Serotonin Reuptake Inhibitors; SNRis, Serotonin Norepinephrine Reuptake Inhibitors; 
TCA, Tricyclic Antidepressants. 
t Includes those treated with medication (n= 17 and n= 21, respectively) 
§for example: Mirtazapine, Bupropion and Trazodone. 
Table 4. Sociodemographic and Clinical Correlates of Depressive and Anxious Symptom Severity at Post-Test (N=49) 
Sociodemographic 
Age 
Marital Status (married) 
Work Status (retired) 
Highest Education (post-secondary) 
Ethnicity (white) 
Annual Family Income ($50,000CDN or greater) 
Children (yes) 
Clinical 
Cardiac Indication 
PC! (yes) 
Angina/ACS/CAD (yes) 
Ml (yes) 
CABG (yes) 
Valve (yes) 
BMI 
Exercise Behavior (Godin) t 
Diabetes (yes) 
Hypertension (yes) 
Dyslipidemia (yes) 
CR Emollment (yes)t 
CR Completion (yes) t 
Psychosocial 
Depression t Anxietyt 
t/r t/r 
-.263 
-.137 
-.020 
.139 
1.203 
-.032 
-.416 
-1.549 
1.699 
-.924 
1.136 
-.848 
.189 
-.302· 
1.486 
.475 
-.376 
-1.468 
-1.418 
-.281 
-.369 
-.845 
.408 
.160 
.030 
-1.306 
-1.409 
-1.364 
-.896 
1.321 
-.381 
.120 
-.155 
.231 
.295 
-1.443 
-1.510 
-.867 
Treatment (yes)t 3.087.. 4.539 .... 
BDI-II .626... .567 ... 
PHQ-2 .548... .528 ... 
PHQ-2t .891... .782 ... 
PCI, Percutaneous Coronary Intervention; ACS, Acute Coronary Syndrome; CAD, Coronary Artery Disease; CON, Canadian dollars; MI, Myocardial 
Infarction; CABG, Coronary Artery Bypass Graft; BMI, Body mass index; BDI, Beck Depression Inventory; PHQ, Patient Health Questionaire 
*p < 0.05; **p <O .01; •••p < 0.001 fort-test and Pearson's correlation (r), as applicable. 
~ t Assessed at post-test. All other variables assessed at pre-test. 
Table 5. Adjusted Multiple Linear Regression Model Examining the Association of Treatment with Depressive and 
Anxious Symptom Severity at Follow-up (N=49) 
Depressive Symptoms Anxiety Symptoms 
Variable p SE p 95%CI p SE p 95°/o CI 
Lower Upper Lower Upper 
Bound Bound Bound Bound 
Treatment -.443 1.483 .768 -3.498 2.612 -2.416 1.431 .104 -5.363 .531 
Psychosocial Distress at .211 .061 .002 .086 .336 .167 .059 .009 .046 .288 
Pre-Test (BDl-11) 
Exercise Behavior Post-test -.022 .039 .581 -.103 .059 -.003 .038 .932 -.081 .075 
(Godin) 
Age -.128 .081 .127 -.296 .039 -.098 .078 .221 -.260 .063 
PCI 1.411 1.403 .324 -1.478 4.300 .536 1.353 .695 -2.251 3.323 
PCI, Percutaneous Coronary Intervention; BDI, Beck Depression Inventory 
CI, Confidence interval; SE Standard Error. 
Extended Results and Discussion 
Overall, we were not concerned about missing clinical data as it was only used to 
describe the sample. However, missing depression and anxiety data was examined. A 
total of 109 (78.4%) participants completed the BDI-11and125 (89.9%) the PHQ-2. Of 
those participants who were retained at follow-up, 110 (99.l %) completed both HADS-D 
andHADS-A. 
We originally proposed to handle missing data with the use of multiple 
imputation. After discussing this with a statistical consulting service consultant through 
the Institute for Social Research at York University, we decided to approach missing data 
using listwise deletion. Although this method decreases sample size and has the potential 
to create bias in the results when dealing with sensitive data, we perceived it was a 
preferable option to imputation which has the potential to create even greater bias. With 
regard to sample size, we had sufficient power to test the hypotheses proposed. 
Moreover, the reason for much of the missing data was a change in assessment tools by 
the investigators after the study had begun (i.e., 28 [21.1 % ] participants were not 
administered the BDI-II at pre-test). Therefore the reason for this missingness was not a 
patient-related bias. Although depression and anxiety could be considered as sensitive by 
patients, the rate of survey completion was high. 
Clinical Implications 
General principles for any kind of screening61 specify that programs should be 
implemented if: (a) the condition is common and (b) associated with significant 
morbidity7'28, ( c) if screening is accurate62•63 , ( d) low cost64, and ( e) there is effective 
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therapy available37•41 '44-46. In the case of co-morbid depression, most of these elements 
appear to be satisfied. However, it suspected there in insufficient capacity to ensure that 
effective therapy is available for all patients who screen positive, especially in the context 
of CR. 
Despite recommended guidelines, our data shows that less than half of women 
reported being screened. Moreover, screening rates did not differ between those who 
enrolled in CR and those who did not. At this time, little is known about screening rates 
in the CR context. A literature search carried out pertaining to depression screening and 
treatment in the cardiac setting identified no information available in the CR context, 
suggesting a gap in this area of research65 . An abstract prepared in the Grace lab 
suggested that 28. 7% of patients recalled being screened for depression since their 
cardiac diagnosis, while 32.5% of those enrolled in CR recalled screening66• This is 
fairly-consistent but somewhat lower than the results reported herein (34.9%). 
Although it has been reported that depression screening alone does not improve 
cardiac patient outcomes66, when screening is combined with adequate follow-up (i.e. 
communication between healthcare providers, frequent check-ins, medication 
adjustments, promotion of treatment adherence, etc) significant improvements can be 
achieved64•67•68• A number of studies have shown the effectiveness of screening in 
combination with adequate follow-up care in improving depressive symptoms64•67•68, 
quality of life 67•68, and physical function 68. These studies suggest that while screening for 
depression on its own is not sufficient to obtain substantive improvements in patient 
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outcomes, it is important to provide patients with a system of care which will assist them 
in achieving significant improvements throughout their rehabilitative process. 
Future Directions 
Unfortunately, there continues to be a lack of evidence for the efficacy of 
screening, and some have suggested that the American Heart Association should 
reconsider their advisory to screen69• However, given the high co-morbidity of CVD and 
depression, as well as the association between depression and adverse outcomes in 
cardiac patients, there appears to be consensus that screening should be undertaken if and 
only if it can be combined with effective and appropriate care. 
Future research is needed to examine screening and treatment of psychosocial 
distress in the CR setting in jurisdictions other than Ontario. These studies should not 
only observe rates of screening in CR, but also the rates of referrals to internal and 
external sources for all patients who screen positive, and the number of follow-up visits 
over time. As stated above, sufficient follow-up appears to be crucial for patients to 
achieve remission. It is not clear what role the CR team plays in follow-up care for 
depressed patients, and how this differs in programs where their staffing complement 
includes a psychologist or psychiatrist. It is important to outline how the CR team could 
be utilized in follow-up for patients who are identified as distressed, as patients have 
repeated contacts with staff on a weekly basis, and there is communication between the 
CR program and other members of the patients' circle of care. 
Moreover, although adequate follow-up seems to be essential for effective 
treatment, it may also be imperative to catch inappropriate treatment. Past research has 
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reported that there is little difference in the efficacy of psychoactive medications in 
treating mild to moderate depression, but differences in adverse effects among the 
medications are significant7°. Over the past two decades, SSRis have become known as a 
first-line pharmacological treatment for depression in cardiac patients, given they are 
shown as both safe and effective in cardiac patients 70• In the past, TCAs were shown to 
successfully treat depression in cardiac patients71 • Unfortunately, it has been identified 
that TCAs can have negative effects on the cardiovascular system, including hypotension, 
pro-arrhythmic effects, cardiac conduction problems and significant drug interactions 70'71 • 
Despite the fact that TCAs are accordingly contraindicated for cardiac patients, our 
results revealed that over 10% of the women who were talcing a psychoactive medication 
were talcing TCAs at pre-test and rates of those on TCAs remained stable at post-test. Our 
results suggest there has been little reduction in the rates of use of these contraindicated 
medications. Benazon et al.72 examined trends in anti-depressant prescription for post-MI 
patients over a decade. It was found that rates of TCA anti-depressant prescriptions 
decreased, but the proportion of post-MI patients receiving TCAs remained stable at 6%. 
Another study examining anti-depressant use in cardiac patients found that 12.5% of 
patients reported taking TCAs 73 • It would be interesting to see if adequate screening rates 
and follow-up in the CR context would have an effect on the number of patients treated 
with contraindicated medications. 
Conclusion 
Rates of psychosocial distress screening in the CR context are low, despite 
clinical recommendations. Given the high co-morbidity of CVD and depression, 
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screening and treatment are important, but sufficient follow-up care seems to be 
imperative for patients to achieve substantive improvements. Little is known regarding 
screening, treatment and follow-up care of depression in the CR setting. It is hoped that 
these preliminary findings spur future research, as well as implementation of more 
systematic processes of CR care to address the mental health needs of cardiac patients. 
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Appendix A: Study Design 
Pictorial Flew Diagram: Cardiac Rehabilitation for Heart Event Rttmrery 
Solicit ooment from patients from inpatient and 
outpatient cardiac settings 
Solicit physician cletiance from patient's genenl 
practitiOilfl" if patieol is recruited from iDpatieot 
Clinical dam atracted 
setting 
Patilmtjilu out initial 
1'roal patimt dttzrts T .mney 
Patients are then nmdomiud to 1 of 3 cardiac 
rehabilitation prog:mn models 
•• 
I ,~ 1 
Home-Based CR Co-Ed Hospilal- Women-Only 
BueclCR. Hospi1al-Based 
J l 
r 
Start of cmliac :rehabilitation progr:am ] 
r 4-6 Months U ~ --
~~ 
Patient :fills Ollf final smvey and post CR clinical data exlracled from 
patimt chart 
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Appendix B: Case Report Form 
L Study ID#: __ _ 
2. Tocby's Da1e 
C PCI 
C CABG 
C Umtable Angim I ACS 
D MI 
dd mmm yyyy 
D MUSCDblrehlbl, aennmmscubr~ vision, cognitive arnan-dyspharic psyclDatDc conditim which precludes 
CR.eligiliility,specify:~-------------~ D Does nat speak/mad :&glish profudy 
D LNes n wam too mfi'am CR.sites (Hwy 4'1:1, acmss Hwy 1 to tar end atSCDbcmmgh) 
0 Pbnaing to hmie tlE province or region in the next 9 mcmdJs 
D Not eligil>lemr ~CR. specify: 
D Compis vmtrimbr dysihythmia 
D Ejection fraction <4091. and/or NYHA Cass> 2 
D CCSClass4 
D Didn't pass GXT at CR.intake(< 3 min toleratl!d of modified Bmce TJe3.dmill Pmtocol) 
CJ &rolled in other study with bebavicmral inten.rmtion 
0 hf'enal 1o CR. pmgmn prior to study r.mdmnizidim1 
CJ Tenniml illness er Jifi!...thratming ·camtitim 
D Bemg~toJaag-tamcare 
D Previous parti.cipldian m CR. so rl!a!llt &it CR. pmgr.am. c1eems pt nat eligible to r:e-emoll 3t 1b:i5 tioE 
D Patient clDes DDt :have c:miiz diagnosis orpmcedme Dll!t!ting inclusian oiteria (e.g., angiogram resuJis 
negative, review of disc:lmge Date) 
0 Physi.cim clen<mee not rPCl!ivecl 
D Physicim does nat deem P3iim eligible Cclear.mce recei.wd, negative respcmse) 
D <>&iec -
5. Pa6mt Dedine to Part:iciprle: 
CNo CYes-~ifwilling: _______________ _ 
6. PI/ lnvestiplol' ccmfinn p3lieJJt eligiole: 
C Eligal1'e Clnetig.D~Reason: -----------------
I 
CRF CoqilefedBy: 
. Date: ______ _ 
CRF Entered By: ______ _ 
Date: __________ _ 
CR.4HER CRF. Vasi.an 4. Jone 10, 2010 Pagel of4 
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Study ID#: ____ _ 
1. Age IJD 
dd mmm. yyyy 
I 
dd mmm yyyy 
10. hidel: Cardiac Ccmditim audfcr Procedme: 
0 
C Primary C LM 
C Ncm-Priumy C RCA 
0 Unbmm 0 LAD 
(cilde: 'fRX./'tmd/ dist) 
c cm: 
c Rmms 
CABG Date: ___ _ 
LM 
CJ R.CA 
CJ LAD (circle: pnm I med I dist) 
CJ Cin: 
c Ramm 
MI Date: 
T 
.AJderior 0 STF.MI 
lol'erior c NSTEMI 
1*ral c Q-Waw 
Postaicr 0 BBB 
Septal 0 NON-Q-Wave 
RtVmlrimhr 0 Unstahle Angina 
0 ACS CcmfimJaticm I>ne.:~---­
D ECG 0 Angiogram D F.m.ymes D S:ymptoms 
D CHF 
D Infection 
D Valve Condition 
D Infection 
D Anhylbmia 
D Congenital HD 
D Cudiomyopathy 
D Aneurysm 
CR4HER CRF. Vasion 4. Iune 10. 2010 
11. Current Medic:atians (t:het:k aH): 
CJ ACE lDhibitms D Aidi--mhytlmac 
CJ .Ami-<."Oagu)ants D Aidi-pbte!ets 
C ASA D Bm-blockers 
Cl Cal+ mtagmllst; 0 Digmin 
CJ Stltin 0 Nitrate (not PIN) 
D IL- fihRte 0 AR& 
D ll-nicotinic acid D Aldi~ 
C IL-I1!Sin chugs D Cammdin 
c Diun!tics 0 Hepmn 
CJ Clopidogrel or Cl HRT 
ticlapidine D Imolin 
CJ Other mti-p1ateJet D Oral 
C Nicotine hypoglycemics 
hpbcemmt 
C,Other: ______ _ 
12. ccs Angim Class: 
Do CJ1 D2 D3 CJ4 
+C IV-aD IV-bC IV-cDIV-d. 
13. NYHA FUlldicmal Class: 
CJI C2 CJ C4 
14. LV F111Lii.on: 
CJ Nuclear D Echo D Al3giogram 
CJ LVEf %: ___ _ 
CJ Namitive: ______ _ 
0 Normal OMild DModer.d:e DSewm! 
0 Date asSl!S!ied: ____ _ 
Cl Cardiac Am!st 
CJ Pericantitis 
CJ PMumania 
C A.Clde Renal Fail 
CJ DVTbrombosis 
CJ Ml 
c~ 
CJ Cardiac 
Tamponade 
CJ Ot1e: specify: 
Page2of4 
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Study ID#: 
-----
16. Risk Factms: 
y N 
D D Diabetes: C Type I C T}'Pe 11 
HbAlc'Y.: __ _ 
Date. assessed: 
----0 D Obesity (BMl>30) 
BMl ().rJmi: __ 
Waist ciR: (cm): 
Dateassessecl: --
0 D Hypertension 
BP: syst I diast 
Date assessed: --
0 D Dyslipidemia 
Total Cholesterol: 
HDL: --
I.DI.: 
Trigfy_ceo __d-es-·· -
Date~--
17.CRP: 
--Date messed: 
---
18. Heart nde: 
Date assessed-
--
19. Previous cudiac .r . ? 
Cf CAD 
D rnF 
D Aohythmia 
D Cmgmital HD 
D ACSJMI 
10 r _1_· .. r .... .... 
D 0mcer 
ll Hyperthyroid 
D Liver Disease 
Cl PADIPVD 
ll DepresRon 
0 Renal Disease 
c Ini!dim 
C Valve conditicm 
c Cantiomyopathy c Other. __ _ 
c Nooe 
Cl MSK I Ioiot Replaceme.ut, specify: 
ll Other: -
CR4HER. CRF. Version 4. Juoe 10~ 2010 
21. Family ph}'Sician: 
Phone mmber: 
22. Cantiac specialist(s): 
23. Clemnce Received: 
D Yes D No 
24. Received By: 
0 Family Physician D Cardiac Specialist 
OBoth 
25. Cleared for CR. refenal: 
D Yes D No 
26. Randnmimf to: 
Cl Home based 
c Coe! lmspita1 based 
Cl Wamen anly 
27. Siterefemd to: D TRI D TWH 
2s. Refeml 0ate: 'L-~-L..1---L...I _ _.I 
dd :mmn yyyy 
29. Call to patient re: progmn site & model: 
0 Yes D No 
Date: 
I I I 
dd 
Notes: 
30. Did patient go off-study'? 
0 Yes D No 
mmn YYYY 
ffyes.specify: _______ _ 
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Stady ID#: ___ _ 
L Patient's First Nm1e: 
2 Patient's Last Ni1111e: 
c Ms.. 
Cl Mrs. 
0 Dr. 
I I I I I I I I I I I 
{Al1!il code) 
S. Pidimt's ~ 
6. Patient's email addn!ss: ____ _ 
CR4HER CRF. Version 4. June 10, 2010 Page4of4 
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°' N 
Name 
(last,Rrst) 
Year of 
Birth 
· Oateof 
Expected 
Date of CR 
ln~=pt OrCcv~fn 
Waist 
Total Triglyce Circumf 
HOL LOL Cholesterol rides ere nee 
CR4HER. V3. May 20, 2011. Page 3of 4 
Peak Cpa? Comments re: GXT. Symptom 
BP METS VOa.a yin limited? 
> 
"t:S 
"t:S 
~ 
= Q.. 
-· ~ 
("') 
.. 
~ 
= ...... ~ 
~ 
~ 
"t:S 
0 
::s. 
~ 
0 
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Appendix D: Assessment of Sociodemographic Characteristics 
SECTIONN: DEMOGRA.PmCS and CARDIAC RISK FACTORS 
1. What do you consider to be }'Olll ntcial/etbnic background? .Please check ~ one (1) of 1b.e following 
boxes: 
a White (Caucasian} 
Cl French-Canadian 
a Jewish 
Cl Anh I West Asian (e.g .• Afghan. Aimmian. Ir.mian. Egyption. ~ Mmmcan) 
DI South Asian (e.g .• East Indian, Punjabi. Pakistani.~~ Sri I.ankan) 
Cl SouthEastAmn (e.g., Cambadian, Jrukmesian, ~ S~ Vietnamese, Thai) 
Cl Chinese 
a Japanese 
a Filipino 
a Korean 
a Black (e.g.. Africm. Haitian, Jamaican, Somali) 
a Latin American 
Cl Aboriginal (e.g .. M~ Jnmt) 
a Other(sperify:~----------
a Multiple cultmalbackgrounds (spedfy: _______ ___, 
2a) Who do }"Oil live with? 
Cl Family~ children, etc.) 
Cl Alone (drip to question #3) 
a Other(specify: ______________ __, 
b) If you do not live alone, how many other people do you live with? (not including yourself): __ _ 
c} Do you live with someone who requires c:aregiving (e.g .. ill ~grandchildren)? 
a Yes 
a No 
d) If~you live with smneone who requires care giving. please describe 1) forwltom you provide~ 
2) the type of care giving you do. 3) the nmnber oUOlll'S in an average week you spend care giving: 
!. __________________________ _ 
2. 
---------------------------
e) If yoa have a spouse or pmtner. would you say hisJher health is (please ~ one): 
D D D D 
Euellent Cood Fair Poor 
CR.4HER Pre-Test V5. August 13, 2012. ID# __ _ Page23 of27 
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3a) Do you have children? 
Cl Yes 
Cl No 
b) Ifcy'es' how many children do you have? _____ # 
4. On avenge, how many homs a week do you usually spend doing bousewmk (e.g~ cooking. cleaning, 
washing)? 
_____ hmm per week 
5_ What is yom marital stalm: 
CJ Mmiedlcommon-law 
a Sepantedfdivmced 
CJ Single 
CJ Widow/Widower 
6. What is 1be highest level of education you have campleted? 
a less Ihm grade 9 
a less than high school 
a coJqJleted high school 
a some college oruoivasity comses 
a completed college or univmity degree 
a Gramate Scbool/ProfessiooaI Program 
7. What is your gross amml family income? 
a $19, 999 or less 
a $20, ooo-$29. 999 
a S3o. ooo-$39, 999 
a $40, ooo-$49, 999 
a S5o. ooo -$59, 999 
a S60. ooo -$69, 999 
a $70,000 or greater 
8. Which option best :matdies yam wmk S!alus? 
a tun-time wm:k 
a part..,time walk 
a full-time caregivel' OJ homemaker (inside your home) 
a~ 
DI receiving dimbility 
a retired 
Cl other: ______ _ 
9a) What is your height? __ feet and __ inches or ( cm) 
b) What is your weight? ___ pounds or ( ___ kgs) 
CR.4HER ~Test V.S. August 13. 2012. IDI# __ _ Page24of27 
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1 O. Please desCiil>e your smoking status: 
D I have DellW smoked 
D I ammtJy smoke 
• How many ciguettes per day on average? ___ cigllrettes per day 
• For how many yeus have yon smoked? years 
D I quit smoking 
• When did yon quit? Month yes: __ _ 
• How many cigarettes per day did you :smoke on avenge? ___ cigarettes per day 
• For how many }tiiIS did you smoke? yea:n 
11. Do you have a histozy of heart disease in your family? 
D Yes 
D No 
12 Do you have high cbolesteml, or 1ate cholesterol-lowering medication? 
DYes 
DNo 
13. Do you have high blood pressure, or take blood pressure medication? 
DYes 
DNo 
14. Did yon e&eicise to the point of getting short ofbreafh on a regobir basis (as an adult) J!!i!! to your cardiac 
event? 
DYes 
DNo 
15. Did a doctor teH yon ihat yon were diagDosed with heart disease before this hospifaliz.alion? 
DYes 
DNo 
If yes, appmximately whm were you diagnosed'! I 
(Momh) {Year) 
16. Have yon previously experienced any of the following health problems? Please .,/ all that apply: 
a Heart Attack 
a Angina 
a Angioplasty (stent) 
CJ B:ypm SmgJ!!Y 
CJ Valve Smgay 
a HeartFai:lme 
a Anhythmia (im!gular heat Ibyfhm) 
a Hearttnnsplant 
D Cantiac device: pacemaker or implantable cantiovater defibrillator 
CJ Stroke I TIA [Le., blocked arteries in neck or bmin) 
CJ Peripben.l VascuJar Disease (e.g., blockages in legs) 
CJ None of the above 
CR.4HER. ~Test V5. August 13, 2012. ID# __ _ Page25 of27 
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Appendix E: Pre-test Depression and Anxiety Assessment 
SECTIONM: TALKING WITH HEALTH CARE PROVIDERS ABOUT MOOD & ANXIETY 
(I) History of Depressed Mood 
1. Have you ever had problems with depressed mood? D YES 0 NO 
lb. H yes, how many yems has it been since you first had problems with depressed mood? __ (yls) 
le. Hyes, how many times in ygµr life have you had problems with depressed mood? __ (times) 
2. Has a health care proyider ever diagnnsed. you with depression? 0 YES 0 NO 
2b. Hy~ how many~ ago were yon fu:st given the diagnosis? ___ (yn) 
2c. Hyes, who diagnosed you with depression? 0 Family doctor 
0 Heart doctor (cardiologist) 
D Psychiatrist m psychologist 
ONurse 
DOther: 
--------
(II) Bistery of Amiety 
3. Have you ever had problems with anxiety? DYES 0 NO 
3b. H yes, how magy yean has it been since you first had problems with anxiety?. ___ (yls) 
4. Has a beilth care izmvisler ereI" WapO!ii=d you with an amrirtx dipdcr? DYES D NO 
4b. H yes, how many years ago were you fu:st given 1he diagnosis? (yn) 
4c. Hyes, mm diagnosed you with amiety? 0 Family doctor 
0 Heart dOctor (cardiologist) 
0 Psychiatrist or psychologist 
ONurse 
OOtber: 
-------~ 
(IIl) Curreat Depression er AnDety 
5. Are you gwently having problems with depfessed mood 01 amiety? 0 YES 0 NO 
5b. Hy~ are you having problems with: 0 Depressed mood 
O.Anziety 
0 Both depressed mood and anxiety 
5c. H yes, who is treating you for these problems? 0 Family doctor 
(check all that apply) 0 Heart doctor {cardiologist) 
0 Psychiatrist or psychologist 
ONurse 
OOther: 0 Not being--treated-. ___ by __ heal_llh_carepuvider 
5d Hy~ what 1reatmenb are you using: 0 Medication (antidepressant or anti--amiety pills) 
{check all 1hat apply) 0 ComPljnglf aJk thenpy 
D&ercise 
DOther: D My depressionf;-......, _ ____,,,anm-.-ety-is_not_being ___ .-tre--a.ted-~ 
CR4BER~Test.. V.5. August 13, 2012. ID# ___ _ Page21 of27 
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(IV) Tre.atmflltfor Depressima or Amiefy 
6. Fbn,-e you~ taken anti-depressant or anti-anxiety medications? 
0 Neveruten 0Itook1b.em in the past 0 I take them now: (name: ______ ___, 
7. Have you ever had counseling or~ tbenpf for depression or anxiety? 
0 Never had 0 I had it in the past 0 fm in COUDSelinglfher now 
{V) Mood and Anxiety Sinc:e Start of Heart Problems 
8. How often do yon feel down or blue hrmzsr ofJPWheart cgndjtigp? 
0 Never 0 Somel'iiofs 0 A lot of 1he time 
Bb. If you answeed Sometimes or A lot of the time, what is your main concezn? 
9. Since being diagooted with a heart pmblen, have any health care providers asked about your mood or 
anxiety? 0 YFS 0 NO 
9b. If yes, who asked about your mood or anxiety? D Family doctor 
{c:beck all that apply) D Heart doctor {cantiologist) 
0 Psychia1rist orpsycbologist 
DNmse 
OOther: 
------
10. Since being diagnosed with a heartpmblern. have you ever been med to fill inumveyor had an 
interview with cpSti.am about your mood or anxiety? 
D Smvey D Intaview 0 Both 0 Neither 
If yes te eidaer smvey or in1eiview: 
lOb. Please describe the smvey or interview: 
lOc. Did anyone 1alk to you aboot 1he results? 0 YES 0 NO 
1 Ocl What happeoednm (cbed all that apply)? 
0 I was prescnl>ed medicine for my mood or anxiety 
D I was refeued to a psychiatrist, psydmlogist or counselor 
0 I was refeued for other mental heaith trea1ment-please specify: _____ _ 
0 My healthcare provider is going to follow-up with me about 1Jlls 
D Nodllog {and I do have problems with mood or anxiety) 
0 Nodllog (and I do not have p"Oblems with mood or anxiety) 
DOther,pleasespecify:~~~~~~~~ 
Oldon'tknow 
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Appendix F: The Beck Depression Inventory-II 
SECTION F: J.IOOD 
Instructions: This qnestionnme consists of 21 groups of statements. Please read each group of statements 
arefidly. and then pick out 1he ene statement in each group 1hat best descn"bes 1he way you have been 
feeling dllring 1he past twe wee~ incltiding today. Mm (X) in 1he box beside the statement that yun 
have picked. Be sure that you do mt choose JDDre than one statement for any groop. 
I. Sadoes 
a I do not feel sad. 
a I feel sad moch of 1he time.. 
a I am sad all 1he time. 
a Iamsosador ...... ~dlatlcan't stand it. ~J'J' .J 
%. Pessimism 
a I am not discouraged about m.Y future. 
a I feel more discoUiasred about my 
future that I used to"De. 
a I do not expect ftllngs to wmk mt for 
me. 
a I feel that my firtme is hopeless and 
will only get wmse. 
3. Past F:aila:re 
a 1 do not feel like a faihJre. 
a I have &iled. mme than I should have.. 
a As I look back on my life, I see a lot of 
failures. 
a I feel I am a complete failure as a 
peISOll. 
4. Loss of Pleasure 
a I get as mich~ as I evermd 
from tbe~s I ·oy_ a I don' . ; . tile · I used to. 
a I~~~P , ~mthethings 
ffi8t I used to eoioy. 
a I can7t .get ~P.eastJre mm the things 
that I uSed to eigoy. 
6. P11Jlislumat FHlUaC!t 
a I dan,t feel I am~ punished 
a Ifeellmaybe~ 
a I~mbe~ 
a I feel I am bemg pmjshed 
·1. Self-Dislib 
Cl I feel 1he same about myself as ever. 
Cl I have lost confidence iii llJYSeit: 
Cl I am disappointed in mysett: 
Cl I dislike :Diyself. 
8. Self-Criti~dnus 
Cl I don't aiticize ~more than usual 
Cl I am more critical Of myself than I used 
tobe. 
Cl I criticize m:mlf for all of PIY &nlfs. 
Cl I blame myself for ewzything bad that 
bappem. 
'· Soitlchl nou~hta or W"W.u 
a I don't have any tboogh1s of tilling 
Cl yCf ~ ofkillim!lll}'RH: bot I 
would not amy~mil 
Cl I would like to kill mvselt: 
Cl I would kill m:ySelfif1bad1he chance. 
10.~ag 
Cl I dOn't ay !RY more than I used to. 
Cl I l"YV mare thin I used to. 
Cl I - J . little thing. Cll~~~ 
11.A~tatimt 
Cl I am no more restless orwauod up than 
usual 
Cl I feel more restless or wound up than 
usual 
Cl I am so restless or aDihted that it is 
hard to stav still. ~ 
Cl I am so reStless or -ted that I have 
to keep moving or ming something. 
ll. Loss of hterot 
Cl I have not lost interest in otber . .-mle 
or activities. r-r 
Cl I am less interested in other people or 
~than before. 
Cl I haVe lost :mpSt of my interest in otiJer 
DeOUleor~. 
Cl n is hard to gefimerested in mytbing. 
CR.4HER.Pre-Test VS. August 13, 2012. ID# __ _ Page 13of27 
68 
13. hdec:Wnaeas 
0 I make decisions about as well as ever. 
0 I :find it more difficutt to make 
d.ecisi.ons 1han usual 
O I have much ~difficoJtv. in 
makiw! decisions than I used to. 
o I have lroublemaking decisions. 
14. Wortldesa:aua 
o I do not feel I am wm1hless. 
0 I don't consider mvself as worlhwhile 
ad useful as I useCl to. 
0 I feel more worthless 1hm other people. 
o I feel utterfy useless. 
0 
15. Loss of Eaergy 
O I have as mucheof!gJ as ever. 
o I have lea enetgy ttiin I used to have.. 
o I don1 have ·mOigh emrgy to do very 
mJCb.. 
0 ~bave·mwghemrgytodo 
16. ~~Patttm 0 lhave~ .~amychangein 
!DJsleepng~ 
O ! S!feP ionieWhat more than umal. 
o I sJeeP somewhat lea 1han usual 
o I sJeej> a lot more than usual 
O I s}eep a lot less than usml. 
O I s1e§> most of the day. 
o Ime~ l-2homseadyandcan'tget 
back to Sleep. 
17. lrritabllity 
O I am no more initable Ihm usoal 
0 I am mare initable thm usual. 
0 I am much more initable than usual 
o I am iirita.ble al 1he time. 
18. Chango in Ap~tite 
a I have not.~ any changes in 
!UY appetite. 
a ~titeis somewhat less than 
a ~is somewhat grea.ter1hm 
a MY ~is mich less than before. 
a MY appetite is~ ~er than mual 
a I Jiave no SDPe1lte at ill. 
a I crave tooa·an of the time. 
19. Co:aemtration Difficulb" 
a I can CODCeiinte as well as ever. 
a I can't c:anceolmte u well as usual 
a It is hard to keep my mind on anything 
far~long. 
a I can't Conceidrate on anything. 
lO. Tlftdaeaa or Fatigue 
a lam no more tired or fatigued thm 
usual 
a I get more tired or fatigued more easily 
tbinmual. 
a I am too tired or fidie:ued to do a lot of 
the~ I used to Clo. 
a I am toe> tired or fafurued to do most of 
the things I used to dO. 
ll. Loas of httrest in Su 
a I.have 1'31 ~any recent changes 
m my iDtaeSt m sex. 
a I am less interested in sex than I used to 
be. 
a I amJDllCh lea interested in sex now. 
a I have lost interest in sex completely. 
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Appendix G: The Patient Health Questionnaire-2 
SECTION G: MOOD CONIINUED 
Not At Several More Nearly 
Over dtepast 2 ~•ow eften have yen been All Days 'Ihm Evezy 
bothered by any ef the fellcnriBg problems? Half the Day 
1. Little interest ar pleasure in doing things 0 1 2 3 
2_ Feeling down, depressed or hopeless 0 1 2 3 
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Appendix H: Morisky's Medication Adherence Scale 
SECTION H: PILL TAKING 
Thinking of the medications PRESCRIBED to you by your doctoI(s). please answer the following qaesti.ons: 
1. Do you ever forget to take your medication? 
OYes 
ONo 
2. Are you careless at times about taking your medication? 
OYes 
0 No 
3. When you feel better~ do you sometimes stop 1aking your medication? 
OYes 
a No 
4. ~if you feel wmse when you take your medicine, do yoa stop taking it? 
OYes 
a No 
5. What percaitage of the time would you say you take your pills as prescn"bed by your doctms'! (0% would 
be not tUing as presmbed at any time, to 10091. taking as prescn'"bed all the time). 
____ % 
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Appendix I: Self-Reported Medication List 
11. Please check your medicatiOD bottles. Please list below the names of all of the medications you are 
cm:rently bking md the dose per day. 
a. f. 
b. g. 
c. h.. 
cl i. 
e. j. 
Other medications 
CR4HER. Post-Test V3. Decamer 10. 2010. IDI# __ _ 29of30 
72 
Appendix J: Godin Leisure-time Exercise Questionnaire 
SECTION E: EXERCISE 
I. Dming a t}'pical 7-Dayperied {a week), bow many time.ion the average do you do the 
following kinds of exercise for more than IS minlltes during your ftee 1ime {write on each line 
the appropriate JDDDber). 
a) STRENUOUS EXERCISE 
~eart be.au rapidly) 
{e.g., I111111ing,jogging, hockey~ football. soccer, 
squash. basketball, cross comdiy sJriing, judo, 
roller ska.ting, vigorous swimming, 
vigorous long distance bicycling) 
b) MODERATE EXERCISE 
{mot exhausting) 
{e.g., &st walking, baseball,~ easy bicycling, 
volleyball badnrint~ easy swimming, alpine skiing, 
popular and follc dancing) 
c) MILD EXERCISE 
{minimal effort) 
(e.g., yoga. archery. fishing from river bank. bowliog. 
horseshoes, golf, snaw-mobiliog, easy waiting) 
Tunes Per Week 
?c Dming a t}'pical 7-Day peried (a week). in your leisme time, haw often do you engage in any 
regular activity kmg enenp to WOl'k up a sweat (heart beats Iapidly)'? 
OFTEN 
1.0 
SOMETIMES 
2.0 
NEVERIRARELY 
3.0 
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Appendix K: Post-test Depression and Anxiety Assessment 
SECTION R: TALKING WITH HEALTH CARE PROVIDERS ABOUT MOOD & ANXIETY 
1. Since being refeaed to cardiac rehab, have you had problems with depressed mood or anxiety? 
DYES ONO 
lb. Hyn, have )"OU bad problems with: 0 Depressed mood 
OAnxiety 
0 Bodi depressed mood and anxiety 
le. If yes, who has 1reatedyoa for these problems'? 0 Family doctor 
(check all that apply) 0 Heart doctor (cardiologist) 
0 Psychiatrist or psydioiogist: 
ONurse 
0 Other.---------
0 Not being treated by health care provider 
ld. H yn, what treatmems have you used: 0 Medi.cation (antidepressant or anti-anxiety pills) 
(cbecl all that apply) 0 Counselinglf alk therapy 
O&ercise 
OOther. 
~---------0 My depress:ionlamiety is not being tinted 
2. Since yon were :refened to cardiac rehab, have any health care povideIS adred about yom mood or 
anxiety? 0 YES 0 NO 
2b. If~ who asked al>out your mood or amiety? 0 Family doctor 
(check all that apply) 0 Heart doctor (cardioJogist) 
0 Psychiatrist or psydiologist 
ONurse 
OOther. 
------
3. Since you were refmed to cardiac rehab, have you eVEl" been asked to fill in a smvey or to have an 
imemew with questions about your mood or amriety'! 
0 Survey 0 Inrerview 0 Bodi 0 Neither 
H yes to either survey or interview: 
lOb. Please desc:n"be 1he survey or ioteiview: 
lOc.. Did anyone talk to you about the :results'? 0 YES 0 NO 
lOd. What happened. nm (checl: an 1bat apply)? 
0 I was prescnbed medicine for my mood or amiety 
0 I was refared to a psychiatrist. psycbologist or OOlIDSelor 
0 I was refeaedfor o1her DEJdal health treatment-please specify: ------
0 My healthcare provider is going to follow-up with me about this 
0 Nothing (md I !le.have problems with mood or anxiety) 
0 Nothing (and I do not have problems with mood or anxiety) 
OOther,pleasespecify:~~~~~~~~-
0 I don7tknow 
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Appendix L: The Hospital Anxiety Depression Scale 
SECTION J: YOUR DIOTIONS 
Instrndions: Read each item below and pot an x in one box for each ggestion which comes closest to how 
you have been feeling in the pt week 
I leel tmse or 'wound up' 
a Most of the time 
a A lot of the time 
a From time to time, ocxasionaDy 
a Notatall 
I still enjoy tile things I used to e•jey 
a Definitely as mich 
a Not quite as mDCh 
a Only a little 
a Hardly at all 
I get a sort of frighteaecl feeling as if 
something awful is abent the happen 
a Vf!!IJ defiDitely and qaile badly 
a Yes. but not too badly 
a A little, but it doesn'twouyme 
a Notatall 
I ca b•gh and see tile funny side of 
thiags 
a As mnch as I always could 
a Not quite as mx:h now 
D Definitely not SO JD1Ch DOW 
a Notatall 
Werryillg tllonghts go thronp my 
mmd 
a A great deal of the time 
a A lot of the time 
a Not too often 
a Vf!!IJ little 
I leel cheerlul 
a Never 
a Notoften 
a Sometimes 
a Most of the time 
I can sit at use and feel relaxed 
a Definitely 
a Usually 
a Notoften 
a Notatall 
I feel as if I am slowed dowa 
a Nearly all the time 
a Veryoften 
a Sometimes 
CJ Notatall 
I get a sort of frightened feeling like 
~butterflies~ iB the sto1112ch 
CJ Notatall 
CJ Occasionally 
CJ Quiteoftm 
a V~often 
I have lost inte.rest in my appearace 
a Definitely 
CJ I don't take as mich care as I should 
a I may not take qaile as mnch r.are 
a I take just as uuch care as ever 
I feel restless as if I •ave to be o• the 
move 
a Very much indeed 
a Quitealot 
CJ Notvaymich 
a Notatall 
I look forward witll eajoyment to 
Wngs 
a Asimch as I ever did 
a Rather less 1han I med to 
a Definitely less than I used to 
a HanDy at all 
I get mdda feelings of panic 
a Very often indeed 
a Quiteoftm 
a Notvayoften 
a Notatall 
I can enjoy a good book or radio or 
tele'rision programme 
a Often 
a Sometimes 
a Notoften 
a Verv seldom 
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Appendix M: Discharge Report Form 
---
l. Participant IDI#: ---
2. Date of data emaction: 
dd mmm yyyy 
3. Did the patient complete 1he program (cilde one)? Yes No 
2b. lf)v:. Date of dischaige: 
dd mmm yyyy 
le. If no, Date last atleDded Rliab: 
2d. If no,, specify whether (circle one): 
2t1. Describe: 
4.. Number of Sessions prescnl>ed (on site or via telephone): ___ _ 
5~ Number of sessions completed (on site or via telephone): ___ _ 
6. Number of Sessions prescnl>ed to drop out fur medical :reason (if 
applicable): __ _ 
7~ Number of Sessions oompleted to drop out fur medical :reason (if 
applicable): __ _ 
8. Blood lipid profile: 
IC 
9. Waist CiR:umference {rm): __ _ 
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10. Discharge F.xen:ise Stress Test 
a Resting blood pressure: __ 
b. Peak METS: 
----
c. Peak VOi: ____ _ 
d. CPA Completed: Yes 
11. Other comments: 
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Appendix N: Psychosocial Distress Categorization 
Receiving trea1ment 
intbefmmof 
pharmacology 
aodfO£ 
psychotherapy 
res No 
l 
(1) 
self reported or 
elevated 
psyc•oseci21 
symptoms+ 
treatmfllt 
No 
Score of~ 14 on Cmn!lltiytdcingai:di 
==, BDI or score of~ 3 1-----..-.. depr:ess;mt MJl!f or 
OD PHQ-2 No ami amDety 
:medicatimi 
Receiving treatment 
in the funn of 
phamw:ology 
aodfor 
psychothenpy 
Yes No 
l 
(2) 
s:e1f nportM or 
elevated 
psyc•oseci21 
symptoms+ no 
treatmeat 
Yes Na 
nose.If 
np«>rRdor 
elented 
p~ 
SJ'DIPiams + 
treatmat 
(coatrolled) 
(4) 
aoself 
reporffdor 
elevated 
psyc•osodal 
symptoms 
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